Harbor Diversified Inc (HRBR)

[surf1944]

Harbor BioSciences Discovery of New Anti-inflammatory Steroids Published in Peer Reviewed Scientific Journal

San Diego, CA – February 1, 2011 – Harbor BioSciences, Inc. (OTCBB: HRBR), a biopharmaceutical company developing novel therapeutics for the treatment of cancer, metabolic and inflammatory diseases, today announced publication of newly discovered anti-inflammatory steroids naturally present in humans. The paper, “Novel components of the human metabolome: the identification, characterization and anti-inflammatory activity of two 5-androstene tetrols,” was published in the journal, “Steroids” [January, Vol.76(1-2)]. Scientists from Harbor BioSciences first identified these tetrols as natural steroids and. pre-clinical studies indicate the usefulness of these compounds in treating inflammation-driven diseases including arthritis, type 2 diabetes, and COPD.

The paper describes 5-androstene tetrols metabolites of DHEA that have anti-inflammatory activity and are found naturally at very low concentrations in humans. Unlike most natural steroids, the tetrols are orally bioavailable and do not undergo extensive metabolism. Tests in animal models show that they have anti-inflammatory activity similar to the commonly prescribed glucocorticoid steroids, but do not appear to have any of the deleterious side effects that frequently accompany glucocorticoid use such as bone loss, immunosuppression, hyperglycemia, glaucoma, cataracts and cognitive disorders. Most importantly, these molecules do not appear to cause anabolic or estrogenic effects and are not toxic in studies to date.

Harbor BioSciences has been issued several patents in the U.S. and Australia covering these compounds with additional patents pending in Europe and Canada. The patents cover formulations, methods of use and solid-state forms of the tetrols.

James M. Frincke, Ph.D., Harbor BioSciences Chief Executive Officer remarked, “The discoveries reported by company scientists are representative of the untapped wealth of pharmaceutical compounds in Harbor BioSciences’ proprietary steroid platform. Because these molecules occur naturally in humans, they have the potential for development as either pharmaceuticals or nutritional supplements. We believe that the profiles of these steroids in combination with their natural oral bioavailability make them ideal candidates to treat inflammation in a broad spectrum of diseases such arthritis, COPD, and type 2 diabetes.”